Rapid Identification of Potential Drugs for Diabetic Nephropathy Using Whole-Genome Expression Profiles of Glomeruli

Figure 5

GO categories and KEGG pathways enriched in the DEGs that were reversed by the drug perturbation. (a), (b) GO categories and KEGG pathways enriched in the DEGs that were reversed by piperlongumine; (c), (d) GO categories and KEGG pathways enriched in the DEGs that were reversed by 15d-PGJ2; (e), (f) GO categories and KEGG pathways enriched in the DEGs that were reversed by vorinostat; (g), (h) GO categories and KEGG pathways enriched in the DEGs that were reversed by trichostatin A.

(a) GO enrichment

(b) KEGG pathway enrichment

(c) GO enrichment

(d) KEGG pathway enrichment

(e) GO enrichment

(f) KEGG pathway enrichment

(g) GO enrichment

(h) KEGG pathway enrichment